Fideuram Intesa Sanpaolo Private Banking S.P.A. Decreases Stock Position in Biogen Inc. $BIIB

Fideuram Intesa Sanpaolo Private Banking S.P.A. cut its stake in Biogen Inc. (NASDAQ:BIIB) by 15.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,973 shares of the biotechnology company’s stock after selling 2,900 shares during the quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Biogen were worth $2,928,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Empowered Funds LLC boosted its position in shares of Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after buying an additional 2,777 shares during the period. Focus Partners Wealth boosted its holdings in Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after acquiring an additional 6,436 shares during the period. Sivia Capital Partners LLC bought a new position in Biogen in the 2nd quarter valued at $216,000. Cerity Partners LLC grew its position in Biogen by 15.3% in the 2nd quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock valued at $5,847,000 after acquiring an additional 6,184 shares during the last quarter. Finally, NewEdge Advisors LLC increased its stake in Biogen by 13.4% in the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock worth $336,000 after purchasing an additional 316 shares during the period. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Price Performance

NASDAQ BIIB opened at $216.12 on Friday. The company has a market cap of $31.91 billion, a PE ratio of 23.19 and a beta of 0.16. The firm’s 50 day moving average price is $196.61 and its 200-day moving average price is $187.03. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $219.72.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. Biogen’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts forecast that Biogen Inc. will post 13.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on BIIB shares. Sanford C. Bernstein decreased their target price on Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and raised their price target for the stock from $185.00 to $225.00 in a research note on Wednesday, April 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biogen in a report on Monday, June 22nd. Mizuho dropped their target price on shares of Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a research note on Monday, June 15th. Finally, Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Biogen has an average rating of “Moderate Buy” and an average target price of $217.41.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.